Industry Partners and Investigators

Minor Building
The IDIC is located in the Minor Building.

Explore How the IDIC Can Support Your Next Clinical Study

The Infectious Disease Innovation Center (IDIC) has state-of-the-art respiratory viral contamination and infectious disease expertise. Review our capabilities and services below. 

Interested in partnering with the IDIC? Please email us at IDIC@fredhutch.org

Clinical Research Capabilities 

Facilities and Equipment

  • Isolation-capable infrastructure to support safe interaction with participants with communicable diseases
  • Over 6,000 square feet of dedicated clinical research space 
  • 11 private clinic rooms with windowed doors for safe and discreet patient monitoring
  • Secure underground parking with direct access for study participants
  • Refrigerator, freezers and controlled room temperature cabinet
  • Biosafety cabinet
  • Centrifuge
  • GeneXpert diagnostic system, enabling rapid testing for pathogens including SARS-CoV-2, RSV, influenza and tuberculosis (TB)

Common Services

  • Participant screening, enrollment and follow-up
  • Clinical assessments, including general and focused history and physical exams
  • Phlebotomy and biospecimen collection
  • Rapid diagnostic testing
  • Biospecimen processing
  • Drug preparation 
  • EKGs and vital signs monitoring
  • Drug administration and safety assessments
exam room

Spacious Exam Rooms

biosafety cabinet

Lab Capabilities: Biosafety Cabinet

Lab Equipment

Lab Capabilities: Centrifuge

wall pass through

State of the art respiratory viral containment: Wall pass through for safe handling of product/samples between clinic zones

exam room

Spacious Exam Rooms

biosafety cabinet

Lab Capabilities: Biosafety Cabinet

Lab Equipment

Lab Capabilities: Centrifuge

wall pass through

State of the art respiratory viral containment: Wall pass through for safe handling of product/samples between clinic zones

Clinical Trial Information

Active Clinical Trials

  • GeoVax: A Phase 2 randomized, multi-center study of GEO-CMO4S1 (SARS-CoV-2 vaccine) versus mRNA SARS-CoV-2 vaccine in patients post cellular therapy for hematological malignancies. Investigator: Josh Hill, MD, FIDSA.
  • Moderna: A Phase 2 study of mRNA-1647 cytomegalovirus vaccine in pts who have undergone allogenic hematopoietic cell transplantation. Investigator: Michael Boeckh, MD, PhD.

Past Trials (not comprehensive)

  • AstraZeneca: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA). Investigator: Jim Boonyaratanakornkit, MD, PhD.

IDIC Information for Fred Hutch Staff

Fred Hutch staff can view IDIC internal resources (e.g. fee sheets, study pipeline) on our IDIC CenterNet page. Fred Hutch credentials are required to access.